Adult treatment panel guidelines (ATP III) for hypercholestrolemia: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Mmir moved page Adult treatment panel guidelines (ATP III) to Adult treatment panel guidelines (ATP III) for hypercholestrolemia) |
||
| (17 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
{{ | __NOTOC__ | ||
{{Hyperlipoproteinemia}} | |||
{{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto: | {{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com] | ||
==Overview== | ==Overview== | ||
The Adult Treatment Panel (ATP III) has adopted a classification for serum [[triglyceride]] level that helps in making treatment decisions. Elevated triglycerides are an independent risk factor for [[coronary heart diseases]]. It is commonly observed in persons with the [[metabolic syndrome]], [[obesity]], [[physical inactivity]], [[smoking]], excess [[alcohol]] intake, high-[[carbohydrate]] diets , [[diabetes type 2]], [[chronic renal failure]], [[nephrotic syndrome]], certain drugs like [[corticosteroid]]s, [[estrogen]]s, [[retinoid]]s and [[genetic]] disorders (familial combined hyperlipidemia, [[familial hypertriglyceridemia]], and [[familial dysbetalipoproteinemia]]). | |||
== | ==LDL Cholesterol and Non-HDL Cholesterol Goals == | ||
<table> | <table> | ||
{|class="wikitable" border="1" style="text-align:center; width: | {|class="wikitable" border="1" style="text-align:center; width:600px;" | ||
|-style="background:#CDC9C9" | |||
| Risk category | |||
| LDL goal, mg/dL | |||
|Non-HDL goal, mg/dL | |||
|- | |||
| CHD and CHD risk equivalent (10 year risk for CHD is >20%) | |||
| < 100 | |||
| < 130 | |||
|- | |||
| Multiple (2+) risk factor (10 year risk for CHD is <20%) | |||
| < 130 | |||
| < 160 | |||
|- | |||
| 0-1 risk factors | |||
| < 160 | |||
| < 190 | |||
|- | |||
|} | |||
ATP III LDL cholesterol and Non-HDL cholesterol goals <ref name="pmid11368702">{{cite journal| author=Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults| title=Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). | journal=JAMA | year= 2001 | volume= 285 | issue= 19 | pages= 2486-97 | pmid=11368702 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11368702 }} </ref> | |||
==Serum Triglyceride Classification == | |||
<table> | |||
{|class="wikitable" border="1" style="text-align:center; width:600px;" | |||
|-style="background:#CDC9C9" | |-style="background:#CDC9C9" | ||
| Classification | | Classification | ||
| Line 25: | Line 50: | ||
|- | |- | ||
|} | |} | ||
ATP III classification for triglyceride levels <ref name="pmid11368702">{{cite journal| author=Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults| title=Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). | journal=JAMA | year= 2001 | volume= 285 | issue= 19 | pages= 2486-97 | pmid=11368702 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11368702 }} </ref> | |||
==References== | ==References== | ||
| Line 32: | Line 59: | ||
[[fr:Hypertriglycéridémie]] | [[fr:Hypertriglycéridémie]] | ||
[[pt:Hipertrigliceridemia]] | [[pt:Hipertrigliceridemia]] | ||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
[[CME Category::Cardiology]] | |||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
| Line 41: | Line 72: | ||
[[Category:Lipid disorders]] | [[Category:Lipid disorders]] | ||
[[Category:Medical conditions related to obesity]] | [[Category:Medical conditions related to obesity]] | ||
Latest revision as of 14:50, 27 February 2018
|
Hyperlipoproteinemia Microchapters |
|
ACC/AHA Guideline Recommendations |
|
Intensity of statin therapy in primary and secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
The Adult Treatment Panel (ATP III) has adopted a classification for serum triglyceride level that helps in making treatment decisions. Elevated triglycerides are an independent risk factor for coronary heart diseases. It is commonly observed in persons with the metabolic syndrome, obesity, physical inactivity, smoking, excess alcohol intake, high-carbohydrate diets , diabetes type 2, chronic renal failure, nephrotic syndrome, certain drugs like corticosteroids, estrogens, retinoids and genetic disorders (familial combined hyperlipidemia, familial hypertriglyceridemia, and familial dysbetalipoproteinemia).
LDL Cholesterol and Non-HDL Cholesterol Goals
| Risk category | LDL goal, mg/dL | Non-HDL goal, mg/dL |
| CHD and CHD risk equivalent (10 year risk for CHD is >20%) | < 100 | < 130 |
| Multiple (2+) risk factor (10 year risk for CHD is <20%) | < 130 | < 160 |
| 0-1 risk factors | < 160 | < 190 |
ATP III LDL cholesterol and Non-HDL cholesterol goals [1]
Serum Triglyceride Classification
| Classification | TG level, mg/dL |
| Normal TG level | < 150 |
| Borderline-high TG level | 150-199 |
| High TG level | 200-499 |
| Very high TG level | >500 |
ATP III classification for triglyceride levels [1]
References
- ↑ 1.0 1.1 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)". JAMA. 285 (19): 2486–97. PMID 11368702.